Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 40

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
— — 3,719 3,719 Net loss— — — — — (35)— (35)Balance at June 30, 202547,691 (2,793)$48 $(75,515)$1,035,563 $(206,391)$4,062 $757,767  

Number of Shares OutstandingAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncomeCommon SharesTreasury SharesCommon StockTreasury StockTotalBalance at December 31, 202346,481 — $46 $— $976,633 $(106,796)$247 $870,130 Vested restricted stock units417 — 1 — — — — 1 Common stock withheld for employee withholding tax liabilities on vested restricted stock units— — — — (382)— — (382)Common stock issued under employee stockpurchase plan56 — — — 1,364 — — 1,364 Stock-based compensation— — — — 25,675 — — 25,675 Purchase of treasury stock, inclusive of excise tax— (837)— (25,121)— — — (25,121)Purchase of capped call transaction, net of tax— — — — (20,112)— — (20,112)Other comprehensive loss (Note 11)— — — — — — (142)(142)Net income— — — — — 27,865 — 27,865 Balance at June 30, 202446,954 (837)$47 $(25,121)$983,178 $(78,931)$105 $879,278 

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 8

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 (In thousands)

(Unaudited)

Six Months EndedJune 30, 20252024Operating activities:  Net (loss) income$(35)$27,865 Adjustments to reconcile net (loss) income to net cash provided by operating activities:  Deferred taxes2